Equities analysts forecast that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will report earnings per share (EPS) of ($0.19) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.21). BioCryst Pharmaceuticals posted earnings of ($0.22) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 13.6%. The firm is scheduled to announce its next earnings report on Thursday, August 3rd.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($0.70) per share for the current fiscal year, with EPS estimates ranging from ($0.83) to ($0.55). For the next year, analysts anticipate that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.89) to ($0.46). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that that provide coverage for BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Thursday, May 4th. The biotechnology company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. BioCryst Pharmaceuticals had a negative return on equity of 296.19% and a negative net margin of 313.02%. The company had revenue of $9.40 million during the quarter, compared to the consensus estimate of $6.13 million. During the same period last year, the company earned ($0.31) EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 95.8% on a year-over-year basis.
A number of research analysts have recently weighed in on BCRX shares. Zacks Investment Research raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Tuesday, April 18th. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 12th. Piper Jaffray Companies reissued an “overweight” rating and issued a $8.00 price objective on shares of BioCryst Pharmaceuticals in a report on Monday, February 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, March 1st. Finally, Ladenburg Thalmann Financial Services started coverage on BioCryst Pharmaceuticals in a report on Thursday, February 16th. They issued a “buy” rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $8.29.
COPYRIGHT VIOLATION NOTICE: This report was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/06/16/zacks-brokerages-anticipate-biocryst-pharmaceuticals-inc-bcrx-will-announce-earnings-of-0-19-per-share-updated-updated-updated.html.
BioCryst Pharmaceuticals (NASDAQ:BCRX) traded down 0.51% during midday trading on Tuesday, reaching $5.81. The company had a trading volume of 854,427 shares. The firm has a 50-day moving average of $6.87 and a 200 day moving average of $6.43. BioCryst Pharmaceuticals has a 1-year low of $2.60 and a 1-year high of $9.25. The company’s market capitalization is $467.24 million.
In related news, insider Thomas R. Staab II sold 6,500 shares of the firm’s stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $8.43, for a total transaction of $54,795.00. Following the sale, the insider now directly owns 123,813 shares of the company’s stock, valued at $1,043,743.59. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Thomas R. Staab II sold 3,250 shares of the firm’s stock in a transaction dated Monday, March 20th. The stock was sold at an average price of $9.20, for a total value of $29,900.00. Following the sale, the chief financial officer now directly owns 144,710 shares in the company, valued at $1,331,332. The disclosure for this sale can be found here. Insiders sold 16,250 shares of company stock worth $139,815 over the last three months. Corporate insiders own 5.80% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. Comerica Bank raised its stake in BioCryst Pharmaceuticals by 18.8% in the fourth quarter. Comerica Bank now owns 16,105 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 2,552 shares during the period. Ellington Management Group LLC bought a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at approximately $110,000. Principal Financial Group Inc. raised its stake in BioCryst Pharmaceuticals by 0.3% in the first quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 45 shares during the period. Wells Fargo & Company MN raised its stake in BioCryst Pharmaceuticals by 29.8% in the third quarter. Wells Fargo & Company MN now owns 28,330 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 6,500 shares during the period. Finally, Bank of America Corp DE raised its stake in BioCryst Pharmaceuticals by 43.3% in the first quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock valued at $210,000 after buying an additional 7,568 shares during the period. 76.88% of the stock is currently owned by hedge funds and other institutional investors.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.